Overview

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis

Status:
Completed

Trial end date:
2007-05-01

Target enrollment:

Participant gender:

Summary

The efficacy and safety of CellCept (1g po, bid for 36 weeks) will be assessed in patients with myasthenia gravis receiving prednisone, or other corticosteroids. During the study, patients will undergo gradual corticosteroid dose reduction, if they respond to treatment. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Collaborator:

Aspreva Pharmaceuticals

Treatments:

Mycophenolate mofetil
Mycophenolic Acid